Clinical Trial

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for people with muscle-invasive bladder cancer (MIBC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-11; most recent amendment 2026-06-23.
Trial Details
NCT Number NCT07414992
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Regeneron Pharmaceuticals
Conditions Bladder Urothelial Carcinoma
Enrollment 44 participants
Start Date 2026-07
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-24